share_log

Insmed | 10-Q: Q3 2024 Earnings Report

SEC ·  Oct 31, 2024 11:05

Summary by Futu AI

Insmed reported strong financial results for Q3 2024, with total revenue increasing 18.2% to $93.4 million compared to $79.1 million in Q3 2023. The growth was driven by ARIKAYCE sales expansion across all regions, with US revenue up 12.9% to $66.9 million, Japan revenue up 30.9% to $21.0 million, and Europe revenue up 45.3% to $5.6 million.Research and development expenses increased to $150.8 million from $109.1 million in Q3 2023, primarily due to higher manufacturing costs and increased headcount. SG&A expenses rose to $118.9 million from $90.6 million, driven by higher personnel costs and commercial readiness activities for brensocatib. The company reported a net loss of $220.5 million compared to $158.9 million in Q3 2023.The company maintained a strong financial position with $461.5 million in cash and cash equivalents plus $1.0 billion in marketable securities as of September 30, 2024. Insmed remains on track to file an NDA for brensocatib in bronchiectasis in Q4 2024 following positive Phase 3 ASPEN trial results. The company also closed screening for the ENCORE study of ARIKAYCE, with topline data expected in Q1 2026.
Insmed reported strong financial results for Q3 2024, with total revenue increasing 18.2% to $93.4 million compared to $79.1 million in Q3 2023. The growth was driven by ARIKAYCE sales expansion across all regions, with US revenue up 12.9% to $66.9 million, Japan revenue up 30.9% to $21.0 million, and Europe revenue up 45.3% to $5.6 million.Research and development expenses increased to $150.8 million from $109.1 million in Q3 2023, primarily due to higher manufacturing costs and increased headcount. SG&A expenses rose to $118.9 million from $90.6 million, driven by higher personnel costs and commercial readiness activities for brensocatib. The company reported a net loss of $220.5 million compared to $158.9 million in Q3 2023.The company maintained a strong financial position with $461.5 million in cash and cash equivalents plus $1.0 billion in marketable securities as of September 30, 2024. Insmed remains on track to file an NDA for brensocatib in bronchiectasis in Q4 2024 following positive Phase 3 ASPEN trial results. The company also closed screening for the ENCORE study of ARIKAYCE, with topline data expected in Q1 2026.

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Comment Comment · Views 285

Recommended